Difference between revisions of "Hairy cell leukemia"
Jump to navigation
Jump to search
m |
m |
||
| Line 7: | Line 7: | ||
==Cladribine (Leustatin)== | ==Cladribine (Leustatin)== | ||
===Regimen #1, Tallman, et al. 1996=== | ===Regimen #1, Tallman, et al. 1996=== | ||
| + | Level of Evidence: | ||
| + | <span | ||
| + | style="background:#EEEE00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase II</span> | ||
| + | |||
*[[Cladribine (Leustatin)]] 0.1 mg/kg/day IV continuous infusion on days 1 to 7 (total dose per cycle: 0.7 mg/kg) | *[[Cladribine (Leustatin)]] 0.1 mg/kg/day IV continuous infusion on days 1 to 7 (total dose per cycle: 0.7 mg/kg) | ||
| Line 12: | Line 20: | ||
===Regimen #2, Zenhäusern, et al. 2009 (SAKK 32/98)=== | ===Regimen #2, Zenhäusern, et al. 2009 (SAKK 32/98)=== | ||
| + | Level of Evidence: | ||
| + | <span | ||
| + | style="background:#00CD00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase III</span> | ||
| + | |||
*[[Cladribine (Leustatin)]] 0.14 mg/kg/day IV continuous infusion on days 1 to 5 (total dose per cycle: 0.7 mg/kg) | *[[Cladribine (Leustatin)]] 0.14 mg/kg/day IV continuous infusion on days 1 to 5 (total dose per cycle: 0.7 mg/kg) | ||
| Line 17: | Line 33: | ||
===Regimen #3, Zenhäusern, et al. 2009 (SAKK 32/98)=== | ===Regimen #3, Zenhäusern, et al. 2009 (SAKK 32/98)=== | ||
| + | Level of Evidence: | ||
| + | <span | ||
| + | style="background:#00CD00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase III</span> | ||
| + | |||
*[[Cladribine (Leustatin)]] 0.14 mg/kg/day IV once per day on days 1, 8, 15, 22, 29 | *[[Cladribine (Leustatin)]] 0.14 mg/kg/day IV once per day on days 1, 8, 15, 22, 29 | ||
| Line 27: | Line 51: | ||
==Pentostatin (Nipent)== | ==Pentostatin (Nipent)== | ||
| − | = | + | Level of Evidence: |
| + | <span | ||
| + | style="background:#EEEE00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase II</span> | ||
| + | |||
*[[Pentostatin (Nipent)]] 5 mg/m2 IV over 2 minutes once per day on days 1 & 2 | *[[Pentostatin (Nipent)]] 5 mg/m2 IV over 2 minutes once per day on days 1 & 2 | ||
Revision as of 01:57, 13 July 2013
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Cladribine (Leustatin)
Regimen #1, Tallman, et al. 1996
Level of Evidence: Phase II
- Cladribine (Leustatin) 0.1 mg/kg/day IV continuous infusion on days 1 to 7 (total dose per cycle: 0.7 mg/kg)
7-day course
Regimen #2, Zenhäusern, et al. 2009 (SAKK 32/98)
Level of Evidence: Phase III
- Cladribine (Leustatin) 0.14 mg/kg/day IV continuous infusion on days 1 to 5 (total dose per cycle: 0.7 mg/kg)
5-day course
Regimen #3, Zenhäusern, et al. 2009 (SAKK 32/98)
Level of Evidence: Phase III
- Cladribine (Leustatin) 0.14 mg/kg/day IV once per day on days 1, 8, 15, 22, 29
5-week course
References
- Tallman MS, Hakimian D, Rademaker AW, Zanzig C, Wollins E, Rose E, Peterson LC. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood. 1996 Sep 15;88(6):1954-9. link to original article contains verified protocol PubMed
- Update: Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005 Jul 1;106(1):241-6. Epub 2005 Mar 10. link to original article contains protocol PubMed content property of HemOnc.org
- Zenhäusern R, Schmitz SF, Solenthaler M, Heim D, Meyer-Monard S, Hess U, Leoncini L, Bargetzi M, Rufener B, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma. 2009 Sep;50(9):1501-11. doi: 10.1080/10428190903131755. link to original article contains protocol PubMed
Pentostatin (Nipent)
Level of Evidence: Phase II
- Pentostatin (Nipent) 5 mg/m2 IV over 2 minutes once per day on days 1 & 2
14-day cycles, continued to the point of maximal response or treatment failure
Supportive medications:
- Allopurinol (Aloprim) 300 mg PO once per day in "the initial courses of treatment" for prophylaxis
References
- Cassileth PA, Cheuvart B, Spiers AS, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol. 1991 Feb;9(2):243-6. link to original article contains protocol PubMed